Figure 6
GDF15 overexpression ameliorates NASH phenotypes and related metabolic deterioration in mice. (a–c) Body weight (a, n = 3–10), food intake adjusted for body weight (b, n = 3–6), relative inflammatory gene expression (left panel of c, n = 3–5) and relative fibrosis-related gene expression (right panel of c, n = 3–5) in GDF15-Tg line 19 and control mice fed MCD diet for 7 weeks. (d–l) Body weight (d, n = 4–11), relative inflammatory gene expression (left panel of e, n = 4–6), relative fibrosis-related gene expression (right panel of e, n = 4–6), fasting glucose level (f, n = 4–11), fasting insulin level (g, n = 4–11), HOMA-IR index (h, n = 4–11), food intake adjusted for body weight (i, n = 4–11), serum ALT/AST levels (j, n = 4–11), liver weight adjusted for body weight (k, n = 4–11) and liver TG content (l, n = 4–11) in GDF15-Tg line 19 and control mice fed AMLN diet for 22 weeks. (m) Relative hepatic Opn mRNA levels in GDF15-Tg line 19 and control mice fed MCD for 7 weeks (left, n = 3–5) or AMLN diet for 22 weeks (right, n = 4–6). Data are means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
